Antigens Patents (Class 435/69.3)
  • Publication number: 20130318648
    Abstract: A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising: (a) contacting a sample from the host with an agent selected from (i) the epitope comprising sequence which is: SEQ ID NO: 1 or 2, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO: 3, (ii) an epitope comprising sequence comprising: SEQ ID NO: 1, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO: 3, which epitope is an isolated oligopeptide derived from a gliadin protein, (iii) an analogue of (i) or (ii) which is capable of being recognised by a T cell receptor that recognises (i) or (ii), which in the case of a peptide analogue is not more than 50 amino acids in length, or (iv) a product comprising two or more agents as defined in (i), (ii) or (iii), and (b) determining in vitro whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is su
    Type: Application
    Filed: November 8, 2012
    Publication date: November 28, 2013
    Applicant: ISIS INNOVATION LIMITED
    Inventors: ROBERT PAUL ANDERSON, ADRIAN VIVIAN HILL, DEREK PARRY JEWELL
  • Publication number: 20130295609
    Abstract: A plant expression system and methods for expressing a protein of interest in a plant are provided. The plant expression system comprises a first nucleic acid sequence regulatory region sequence, operatively linked with a one or more than one comovirus enhancer, a nucleotide sequence of interest, one or more than one geminivirus amplification elements, and a second nucleic acid encoding a geminivirus replicase. The method of producing a protein of interest in a plant, involves introducing the plant expression system into a plant, or portion of the plant, and incubating the plant or the portion of the plant under conditions that permit the expression of the nucleotide sequence and producing the protein of interest.
    Type: Application
    Filed: November 3, 2011
    Publication date: November 7, 2013
    Applicant: MEDICAGO INC.
    Inventors: Marc-Andre D'Aoust, Pierre-Olivier Lavoie, Louis-Philippe Vezina
  • Publication number: 20130295162
    Abstract: The disclosure provides a tetravalent Dengue virus vaccine, and methods of inducing a immune response against a Flavivirus such as Dengue virus 1-4 using the vaccine. The disclosure also provides methods of making a vaccine by introducing into a host cell a transgene that encodes a protein comprising Dengue domain III polypeptides, or, by purified dill polypeptides specific for Dengue serotypes 1-4, Yellow Fever Virus, West Nile Virus, Japanese Encephalitis Virus, and Flaviviruses.
    Type: Application
    Filed: October 3, 2011
    Publication date: November 7, 2013
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Jacob J. Schlesinger, Xia Jin, Robert C. Rose, Olivia K.T. Block, W.W. Shanaka I. Rodrigo
  • Publication number: 20130295610
    Abstract: Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular embodiments, the compounds and methods elicit immune responses against antigens that are otherwise recognized by the host as “self” antigens. The immune response is enhanced by presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises a xenotypic antibody fragment. By virtue of the target binding domain, antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response.
    Type: Application
    Filed: May 22, 2013
    Publication date: November 7, 2013
    Inventors: Rajan George, Lorne Tyrrell, Antoine Noujaim, Dakun Wang, Allan Ma
  • Patent number: 8574584
    Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: November 5, 2013
    Assignee: University of Pittsburgh —of the Commonwealth System of Higher Education
    Inventors: Walter J. Storkus, Michael S. Klnch
  • Publication number: 20130273606
    Abstract: The invention relates to a nucleic acid molecule encoding a multimeric precursor which after transcription is specifically cleaved in vivo to form multiple copies of a protein of interest. The invention further relates to a cell comprising this nucleic acid molecule and a method for producing a protein of interest using this cell.
    Type: Application
    Filed: April 18, 2013
    Publication date: October 17, 2013
    Inventors: Anna Cornelia Hendrika VAN HAUTUM, Arjo Lysander DE BOER, Jan Bastiaan BOUWSTRA, Peter Franciscus Theresius Maria VAN ASTEN
  • Publication number: 20130266604
    Abstract: Described herein is a peptide, referred to as a GlycoTag peptide, that includes repeats of an N-linked glycosylation sequon that is naturally present in C. jejuni. The GlycoTag peptide can be in a purified and isolated form following expression of a construct encoding the GlycoTag peptide or it is, in whole or in part, a synthetic peptide. The GlycoTag peptide is typically used with glycans attached thereto. The GlycoTag peptide can be used alone or in combination with different proteins or peptides and can be incorporated into a chimeric protein or peptide for use in the development of antigen/antibody delivery systems, the preparation of vaccines, pharmaceuticals and diagnostic tests, and research into therapies for countering Campylobacter and other infections.
    Type: Application
    Filed: September 2, 2011
    Publication date: October 10, 2013
    Inventors: Christine Szymanski, Harald Nothaft
  • Publication number: 20130251744
    Abstract: The present invention provides a particle comprising a polypeptide and at least one antigen, and a composition comprising thereof.
    Type: Application
    Filed: February 15, 2013
    Publication date: September 26, 2013
    Applicant: VLP THERAPEUTICS, LLC
    Inventors: Ryuji UENO, Wataru AKAHATA
  • Patent number: 8541003
    Abstract: SARS (severe acute respiratory syndrome virus, a coronavirus) immunogens, antigens, or epitopes, nucleic acid molecules encoding such immunogens, antigens, or epitopes; vectors containing such nucleic acid molecules, e.g., viral vectors such as baculovirus vectors, DNA vectors, such as DNA plasmid vectors, e.g., DNA plasmids that express a nucleic acid molecule in a mammalian cell, uses for such immunogens, antigens or epitopes and vectors, e.g., as an active component immunogenic, immunological or vaccine compositions, or to generate antibodies, such as monoclonal antibodies, and methods for making, and using such immunogens, antigens or epitopes, vectors, antibodies, including in methods for eliciting an immunological or immunogenic or vaccine response, as well as in assays or diagnostic kits or methods, are discussed, as well as a seamless fusion of sequences in a plasmid or vector, e.g., a sequence encoding a leader sequence and a sequence encoding a protein, epitope or immunogen or antigen.
    Type: Grant
    Filed: June 21, 2004
    Date of Patent: September 24, 2013
    Assignee: Protein Sciences Corporation
    Inventors: D. Karl Anderson, Kathleen M. Holtz-Corris, Rick Chubet, Daniel Adams, Manon Cox
  • Publication number: 20130243767
    Abstract: A molecule or molecule complex capable of binding to TLR9 and to CD32 comprising at least one epitope of at least one antigen, and its use a medicament for the treatment of allergies.
    Type: Application
    Filed: March 8, 2013
    Publication date: September 19, 2013
    Inventor: Geert Mudde
  • Publication number: 20130237689
    Abstract: The production of soluble HLA class II molecules, as well as methods of using the soluble HLA class II molecules so produced, are described herein.
    Type: Application
    Filed: April 10, 2013
    Publication date: September 12, 2013
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA
    Inventors: William H. Hildebrand, Steven Cate
  • Publication number: 20130236469
    Abstract: An antigenic composition comprises several antigenic components derived from antigens of Streptococcus equi subsp. equi or subsp. zooepidemicus, wherein at least one component is a fusion protein or polypeptide comprising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals against S. equi subsp. equi and/or subsp. zooepidemicus. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.
    Type: Application
    Filed: May 25, 2011
    Publication date: September 12, 2013
    Applicant: Intervacc AB
    Inventors: Bengt Guss, Jan-Ingmar Flock, Lars Frykberg, Margareta Flock
  • Publication number: 20130230529
    Abstract: Described herein are isolated paramyxovirus, a morbillivirus (FmoPV), isolated nucleic acids encoding the genome of FmoPV, isolated amino acid sequences of FmoPV proteins, antibodies to FmoPV and its proteins, and uses thereof. In certain embodiments, the modified FmoPV is a feline morbillivirus. Also described herein is a recombinant FmoPV comprising a modified FmoPV gene or gene segments and the use of such a virus. The recombinant FmoPV may be used in the prevention and/or treatment of diseases related to FmoPV or as a delivery vector. Also described herein is a diagnostic assay for the FmoPV. In certain embodiments, the FmoPV causes kidney disease. In certain embodiments, the kidney disease is in felines. In certain embodiments, the kidney disease is tubulointerstitial nephritis (“TIN”). Also described herein is a quantitative assay for the detection of the FmoPV, natural or artificial variants, analogs, or derivatives thereof.
    Type: Application
    Filed: January 22, 2013
    Publication date: September 5, 2013
    Applicant: The University of Hong Kong
    Inventors: Kwok-Yung Yuen, Patrick Chiu-Yat Woo, Susanna Kar-Pui Lau
  • Patent number: 8524868
    Abstract: The present invention relates to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of n-polymeric polypeptide, wherein n is an integer from 1-180; to a chimeric protein consisting of a polypeptide of the present invention and a conserved fragment of hemagglutin antigen from influenza virus; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3 or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: September 3, 2013
    Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen University
    Inventors: Ningshao Xia, Jun Zhang, Shaowei Li, Shengxiang Ge, Ying Gu, Zhiqiang He
  • Publication number: 20130224246
    Abstract: A composition comprising a hepatitis C virus (HCV) Envelope 2 (E2) polypeptide including a receptor binding variant, wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597; and wherein the polypeptide forms substantially fewer multimers by intermolecular disulfide bonding relative to the HCV E2 polypeptide without cysteine modification, and substantially retains CD81 binding; and various uses thereof.
    Type: Application
    Filed: August 4, 2011
    Publication date: August 29, 2013
    Inventors: Heidi Drummer, Kathleen McCaffrey, Pantelis Poumbourios
  • Publication number: 20130224236
    Abstract: The invention provides HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Application
    Filed: November 3, 2011
    Publication date: August 29, 2013
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: David M. Koelle, Lichen Jing
  • Publication number: 20130216566
    Abstract: SARS (severe acute respiratory syndrome virus, a coronavirus) immunogens, antigens, or epitopes, nucleic acid molecules encoding such immunogens, antigens, or epitopes; vectors containing such nucleic acid molecules, e.g., viral vectors such as baculovirus vectors, DNA vectors, such as DNA plasmid vectors, e.g., DNA plasmids that express a nucleic acid molecule in a mammalian cell, uses for such immunogens, antigens or epitopes and vectors, e.g., as an active component immunogenic, immunological or vaccine compositions, or to generate antibodies, such as monoclonal antibodies, and methods for making, and using such immunogens, antigens or epitopes, vectors, antibodies, including in methods for eliciting an immunological or immunogenic or vaccine response, as well as in assays or diagnostic kits or methods, are discussed, as well as a seamless fusion of sequences in a plasmid or vector, e.g., a sequence encoding a leader sequence and a sequence encoding a protein, epitope or immunogen or antigen.
    Type: Application
    Filed: June 21, 2004
    Publication date: August 22, 2013
    Inventors: D. Karl Anderson, Kathleen M. Holtz-Corris, Rick Chubet, Daniel Adams, Manon Cox
  • Publication number: 20130216563
    Abstract: The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed.
    Type: Application
    Filed: August 1, 2012
    Publication date: August 22, 2013
    Inventors: Neil Berinstein, James Tartaglia, John A. Tine, Philippe Moingeon, Thierry Boon-Falleur, Pierre Vander Bruggen
  • Patent number: 8513397
    Abstract: Plant viral vectors have great potential in rapid production of proteins, but no simple. Here a geminivirus-based system for high-yield and rapid production of oligomeric protein complexes, including virus-like particle (VLP) vaccines and monoclonal antibodies (mAbs) is described. In particular, a single vector that contains two non-competing replicons for transient expression in Nicotiana benthamiana leaves is described. The correct assembly of these subunit proteins into functional oligomeric structures (VLPs or full-size mAb) is also described. This system advances plant transient expression technology by eliminating the need for non-competing viruses, and thus, enhances the realistic commercial application of this technology for producing multiple-subunit protein complexes.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: August 20, 2013
    Assignee: The Arizona Board of Regents for and on behalf of Arizona State University
    Inventors: Hugh S. Mason, Zhong Huang, Qiang Chen, Charles J. Arntzen, Shuo Yuan, Brooke Hjelm
  • Patent number: 8506964
    Abstract: A fusion protein comprising an antigenic fragment of apoB-100 and a suitable carrier and related compositions methods and systems.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: August 13, 2013
    Assignee: CardioVax, LLC
    Inventors: Jan Nilsson, Goran K. Hansson, Jan Holmgren
  • Publication number: 20130202647
    Abstract: Disclosed herein are chloroplast transformation vectors constructed to enable expression and hyperaccumulation of membrane proteins in chloroplasts. Another embodiment relates to plants transformed with such vectors. Another embodiment relates to seeds and other plant tissues transformed with such vectors. Another embodiment relates to a method of increasing expression of membrane proteins in chloroplasts including transforming a plant cell with vectors described herein.
    Type: Application
    Filed: December 17, 2012
    Publication date: August 8, 2013
    Applicant: University of Central Florida Research Foundation, Inc.
    Inventor: Henry Daniell
  • Publication number: 20130202627
    Abstract: Use of flagellins from the genus Marinobacter as vaccine adjuvants. This invention is based on the use of two recombinant flagellins, F and FR, from the species Marinobacter algicola (DG893T strain), as vaccine adjuvants capable of developing a specific immune response, against peptides or proteins fused to said flagellins, or administered unfused jointly with the flagellins. This invention also describes new combined vaccination strategies, based on the two Marinobacter algicola flagellins and the Salmonella typhimurium flagellin.
    Type: Application
    Filed: February 2, 2010
    Publication date: August 8, 2013
    Applicant: INSTITUTO NACIONAL DE INVESTIGACIÓN Y TECNOLOGÍA AGRARIA Y ALIMENTARIA (INIA)
    Inventor: Eduardo Gómez Casado
  • Patent number: 8501926
    Abstract: The present invention features immunogenic compositions based on pre-fertilization or post-fertilization antigens expressed in the circulating gametocytes in the peripheral blood of infected persons or on the malaria parastes' stages of development in the mosquito midgut including extracellular male and female gametes, fertilized zygote and ookinete. The invention also features methods to prevent the transmission of malaria using the immunogenic compositions of the invention.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: August 6, 2013
    Assignees: The Johns Hopkins University, The United States of America, as represented by the Secretary of the Army
    Inventors: Nirbhay Kumar, Evelina Angov
  • Publication number: 20130198897
    Abstract: The present invention is directed to targeting genes and genomes, modifying the activity of enzymes and protein expression in plants. In particular, the present invention relates to methods for reducing the activity of one or more endogenous glycosyltransferases such as N-acetylglucosaminyltransferase, ?(1,2)-xylosyltransferase and a(1,3)-fucosyl-transferase in a plant cell and to plants obtained by said method.
    Type: Application
    Filed: March 22, 2011
    Publication date: August 1, 2013
    Applicant: PHILIP MORRIS PRODUCTS S.A.
    Inventors: Karen Keiko Oishi, Dionisius Elisabeth Antonius Florack, Prisca Campanoni, Carlo Massimo Pozzi, Jeremy Catinot, Nicolas Joseph Marie Sierro, Nikolai Valeryevitch Ivanov
  • Publication number: 20130189715
    Abstract: Disclosed is the cloning, expression and purification of a hemolysin protein and its protein fragments in Anaplasma phagocytophilum. The recombinant hemolysin and its protein fragments are useful in the ELISA detection of anaplasma pathogen. The use of same as a kit for ELISA is also disclosed.
    Type: Application
    Filed: July 30, 2012
    Publication date: July 25, 2013
    Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLC
    Inventors: John G. Hoey, Denise P. Dimitrov, Lisa P. Huang, Martin E. Adelson, Eli Mordechai
  • Publication number: 20130183341
    Abstract: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plant lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.
    Type: Application
    Filed: January 4, 2013
    Publication date: July 18, 2013
    Applicant: MEDICAGO INC.
    Inventor: MEDICAGO INC.
  • Patent number: 8481332
    Abstract: A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and T-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against Haemophilus influenzae, Streptococcus pneumoniae or Neisseria meningitidis.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: July 9, 2013
    Assignee: Stichting Voor de Technische Wetenshappen
    Inventors: Waltherus Jacobus Wilhelmus Van Venrooij, Jan Wouter Drijfhout, Martinus Adrianus Maria Van Boekel, Gerardus Jozef Maria Pruijn
  • Publication number: 20130171185
    Abstract: The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric VP1 proteins, virus-like particles that contain a chimeric norovirus VP1 protein, and to immunogenic compositions.
    Type: Application
    Filed: July 5, 2011
    Publication date: July 4, 2013
    Inventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
  • Publication number: 20130171182
    Abstract: The invention provides a protein comprising a first and a second copy of hepatitis B core antigen (HBcAg) in tandem, in which one or both of the copies of HBcAg comprises influenza virus A surface polypeptide M2 or a fragment thereof in the e1 loop.
    Type: Application
    Filed: October 22, 2010
    Publication date: July 4, 2013
    Applicant: iQUR Limited
    Inventors: Michael Anthony Whelan, William Malcolm Rosenberg, Lucy Phillipa Beales
  • Publication number: 20130171140
    Abstract: The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.
    Type: Application
    Filed: June 24, 2011
    Publication date: July 4, 2013
    Applicant: VACCIBODY AS
    Inventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
  • Publication number: 20130164313
    Abstract: The present invention relates to the provision of DNA sequences of group 4 major allergens from cereals. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for in vitro and in vivo diagnosis of pollen allergies.
    Type: Application
    Filed: November 16, 2010
    Publication date: June 27, 2013
    Inventors: Andreas NANDY, Helmut Fiebig, Oliver Cromwell
  • Publication number: 20130164782
    Abstract: A method for the secretory production of a glycoprotein having a human-type sugar chain, comprising a step of introducing a gene of an enzyme capable of performing a transfer reaction of a galactose residue to a non-reducing terminal acetylglucosamine residue, and a gene of heterologous glycoprotein, to obtain a transformed plant cell, a step of culturing the plant cell, and a step of recovering the culture medium of the plant cell.
    Type: Application
    Filed: September 14, 2012
    Publication date: June 27, 2013
    Applicant: Phyton Holdings, LLC
    Inventors: Kazuhito FUJIYAMA, Tatsuji Seki
  • Patent number: 8470372
    Abstract: Provided is a fusion protein, which comprises human papillomavirus E7 antigen, virus capsid protein and molecular chaperone. Also provided is a macromolecule with immunogenicity aggregated by the fusion proteins. The particle morphology of the macromolecule is different from that of the virus-like particle. The macromolecule can be used for treatment of human papillomavirus relating diseases.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: June 25, 2013
    Assignees: Shanghai Zerun-Ankegens Biopharmaceutical Company, Ltd., Yunxu CAO
    Inventor: Yunxu Cao
  • Publication number: 20130156805
    Abstract: The present invention regards polypeptides capable of eliciting an immunological response that is protective against Chlamydia trachomatis. The polypeptide comprises a first amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 1 and a second amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 2. Furthermore, production of these polypeptides and pharmaceutical compositions comprising them are also provided.
    Type: Application
    Filed: May 27, 2011
    Publication date: June 20, 2013
    Applicant: SPIXIA BIOTECHNOLOGY AB
    Inventors: Sören Andersson, Åke Strid
  • Publication number: 20130157310
    Abstract: The present invention includes a method to produce a recombinant mite Group 1 protein in a methyltrophic yeast or an Escherichia coli microorganism. The present invention also relates to a recombinant mite Group 1 protein obtained by such a method, such a recombinant protein being able to selectively bind IgE or cause proliferation of a T cell that proliferates in response to a native mite Group 1 protein. Also included in the present invention is the use of such a recombinant mite Group 1 protein to detect mite allergy or to reduce an allergic response to a mite Group 1 protein. The present invention also includes novel mite Group 1 nucleic acid molecules, proteins, recombinant molecules, and recombinant cells, as well as uses thereof.
    Type: Application
    Filed: February 21, 2013
    Publication date: June 20, 2013
    Applicant: MERCK PATENT GMBH
    Inventor: Merck Patent GmbH
  • Patent number: 8465945
    Abstract: The present invention includes a method to produce a recombinant mite Group 1 protein in a methyltrophic yeast or an Escherichia coli microorganism. The present invention also relates to a recombinant mite Group 1 protein obtained by such a method, such a recombinant protein being able to selectively bind IgE or cause proliferation of a T cell that proliferate in response to a native mite Group 1 protein. Also included in the present invention is the use of such a recombinant mite Group 1 protein to detect mite allergy or to reduce an allergic response to a mite Group 1 protein. The present invention also includes novel mite Group 1 nucleic acid molecules, proteins, recombinant molecules, and recombinant cells, as well as uses thereof.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: June 18, 2013
    Assignee: Merck Patent GmbH
    Inventors: Elaine A. Best, Martin J. McDermott
  • Patent number: 8460674
    Abstract: The invention provides HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: June 11, 2013
    Assignee: University of Washington
    Inventor: David M. Koelle
  • Patent number: 8455206
    Abstract: The gene associated and causative of classical late infantile neuronal ceroid lipofuscinosis (LINCL), CLN2, has been identified and characterized. The translation product of this gene is a novel protease and a deficiency in this activity results in LINCL. Identification of CLN2 will not only aid in the prevention of LINCL through genetic counseling but provides strategies and test systems for therapeutic intervention. In addition, further characterization of this previously unknown lysosomal enzyme may provide useful insights into other more common human neurodegenerative disorders. Finally, the utility of a general approach for determining the molecular bases for lysosomal disorders of unknown etiology has been demonstrated.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: June 4, 2013
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventors: Peter Lobel, David Sleat
  • Patent number: 8450087
    Abstract: The invention concerns a recombinant vector characterized in that it comprises a polynucleotide comprising a central initiation cis-active region (cPPT) and a termination cis-active region (CTS), the regions being of retroviral or retroviral-like origin, and the vector further comprising a predetermined nucleotide sequence (transgene or nucleotide sequence of interest) and retrotranscription regulating, expressing, and packaging signals of retroviral or retroviral-like origin.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: May 28, 2013
    Assignees: Institut Pasteur, Institut National de la Santé´ et de la Recherche Médicale, Centre National de la Recherche Scientifique
    Inventors: Pierre Charneau, Véronique Zennou, Hüseyin Firat
  • Publication number: 20130129755
    Abstract: We describe a method of expressing a recombinant protein comprising mannose-terminated N-glycans from a host cell, the method comprising: (a) introducing a nucleic acid encoding a recombinant protein into a Chinese Hamster Ovary (CHO) cell comprising a mutation in the GnT 1 gene (GenBank Accession Number AF343963) leading to loss of GnT 1 function; and (c) expressing the recombinant protein from the host cell, in which the expressed recombinant protein comprises a mannose-terminated glycan structure, and in which the method does not include a step of introducing functional GnT-1 into the host cell. The method may be used for producing recombinant glucocerebrosidase with a mannose-terminated glycan structure, suitable for treatment or prevention of Gaucher's Disease.
    Type: Application
    Filed: March 24, 2011
    Publication date: May 23, 2013
    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Zhiwei Song
  • Publication number: 20130129742
    Abstract: The present invention relates to a polypeptide, described as a lectin, its encoding nucleic acid sequence and antibodies to the polypeptide and their use in various medical applications, particularly for treating or preventing an autoimmune disorder, an inflammatory disorder or damaged skin in an animal.
    Type: Application
    Filed: April 28, 2011
    Publication date: May 23, 2013
    Applicant: LEUKOLECT AS
    Inventors: Bernt Th. Walther, Mirushe Miftari
  • Publication number: 20130129766
    Abstract: Accordingly, the invention provides constructs in which the nucleic acids encoding Plasmodium falciparum MSP4 and MSP5, and the resulting polypeptides, have been modified. More particularly, this invention provides constructs encoding recombinant MSP4 and MSP5 polypeptides, which are expressed as soluble, secreted polypeptides in a baculovirus-insect cell expression system. It was surprisingly found that the recombinant polypeptides contain an EGF-like domain at the C-terminus that is properly folded in the polypeptide.
    Type: Application
    Filed: November 1, 2012
    Publication date: May 23, 2013
    Inventors: Shirley LONGACRE, Hannah POLSON, Ronald PERRAUT, Faridabano NATO
  • Publication number: 20130129764
    Abstract: The invention relates to compositions and methods for the detection of various infectious organisms, including heartworm (Dirofilaria immitis), Ehrlichia Canis, Anaplasma phagocytophilum, and Borrelia burgdorferi. More particularly, this invention relates to antibodies that bind to a heartworm antigen, the E. Canis gp36 polypeptide, the A. phagocytophilum p44 polypeptide, the B. burgdorferi OspA, OspC, OspF, p39, p41 and VlsE polypeptides, and uses thereof.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 23, 2013
    Applicant: VCA Antech, Inc.
    Inventor: VCA Antech, Inc.
  • Publication number: 20130122034
    Abstract: The novel protein SA1789 from Staphylococcus aureus is provided as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Also provided is a composition, particularly a S. aureus vaccine, comprising SA1789 protein or a fragment or derivative thereof capable of generating an immune response that leads to the killing and clearance of S. aureus.
    Type: Application
    Filed: July 8, 2011
    Publication date: May 16, 2013
    Inventors: Tessie B. McNeely, Hongxia Fan, Mark Andrew Miller
  • Publication number: 20130123467
    Abstract: The invention provides for methods and systems for engineering target proteins, based on protein sequence characteristics that influence the likelihood of obtaining a crystal suitable for X-ray structure solution, to improve protein crystallization, as well as related material.
    Type: Application
    Filed: October 19, 2012
    Publication date: May 16, 2013
    Applicant: The Trustees of Columbia University in the City of New York
    Inventor: The Trustees of Columbia University in the City of
  • Patent number: 8440427
    Abstract: A polynucleotide sequence is provided comprising a nucleic acid sequence encoding recombinant Protective Antigen (rPA). Also provided are expression vectors and host cells comprising the polynucleotide sequence of the invention, and methods for producing rPA.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: May 14, 2013
    Assignees: Health Protection Agency, Dynport Vaccine Company LLC
    Inventors: John Brehm, Ian McEntee, Philip Vincent, Nigel Allison, Rossalyn Brehm, George Jack, Michael Herbert, Barbara T. Solow, Juan Arroyo, Randall K. Lapcevich
  • Publication number: 20130115234
    Abstract: The present invention provides a polynucleotide, polypeptide, recombinant modified vaccinia virus Ankara (rMVA) and related vaccine compositions and methods useful in the prevention and treatment of an influenza viral infection. Provided is an isolated polynucleotide encoding multiple copies of M2 influenza ectodomain peptides or rMVA comprising the polynucleotide. Also provided are methods for inducing an immune response to a subject against an influenza virus or for treating a disease or symptom caused by or resulting from infection with an influenza virus.
    Type: Application
    Filed: March 28, 2011
    Publication date: May 9, 2013
    Applicant: Emergent Product Development Gaithersburg,Inc.
    Inventors: Tina Guina, Michael Lacy, Mario Skiadopoulos, Nutan Mytle
  • Publication number: 20130115219
    Abstract: The present invention provides an expression vector for cell-surface expression of proteins.
    Type: Application
    Filed: February 28, 2011
    Publication date: May 9, 2013
    Applicant: F. Hoffmann-La Roche AG
    Inventors: Jeremy Beauchamp, Anita Dreyer, Hugues Matile
  • Patent number: 8435522
    Abstract: Disclosed are humanized antibodies that bind specifically to the receptor CXCR3. The humanized antibodies may be antagonists and may be used to treat or diagnose conditions associated with CXCR3 function.
    Type: Grant
    Filed: January 29, 2008
    Date of Patent: May 7, 2013
    Assignee: Teva Biopharmaceuticals USA, Inc.
    Inventors: Rodger Smith, Palanisamy Kanakaraj, Viktor Roschke
  • Patent number: 8435760
    Abstract: The present invention relates to an expression system for the expression of proteins and peptides in a methanotrophic bacterium, preferably M. capsulatus. Further, the invention relates to the exportation and display of said peptides and proteins on the surface of said bacteria. The invention also describes a method for the production of a desired protein in M. capsulatus.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: May 7, 2013
    Assignee: Stiftelsen Universitetsforskning
    Inventors: Johan R. Lillehaug, Harald B. Jensen